Market Eyes LiveCardinal Health, Inc. (CAH) Stock Rating & Analysis
MELANY's data-driven read on Cardinal Health, Inc. · Wholesale-Drugs, Proprietaries & Druggists' Sundries.
Cardinal Health is one of three leading US pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty pharmaceuticals to pharmacies (retail chains, independents, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson together hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Why CAH scores 59/100
MELANY scores Cardinal Health, Inc. 59/100 by weighing eight factors. Here is how CAH breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 16.6x, earnings growth accelerating
- PEG ratio 1.15 (< 1 = undervalued)
- FCF yield 8.7%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +14%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for CAH
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Cardinal Health, Inc. sits in the Healthcare sector theme, which MELANY currently rates 56/100 for strength. Theme strength feeds CAH's momentum and catalyst factors above.
Tracking CAH
Cardinal Health, Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add CAH to your watchlist and get alerted the moment the rating changes.
How MELANY rates CAH
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Cardinal Health, Inc.'s 59/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CAH
Is Cardinal Health, Inc. (CAH) a buy?
As of 2026-08-25, MELANY rated Cardinal Health, Inc. Hold with a composite score of 59/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Cardinal Health, Inc.'s MELANY score?
Cardinal Health, Inc. (CAH) has a MELANY composite score of 59/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the CAH stock rating calculated?
MELANY scores CAH from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Cardinal Health, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Cardinal Health, Inc. (CAH) Hold with a composite of 59/100 as of 2026-08-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CAH stock price forecast?
MELANY does not publish price targets or forecasts for CAH. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 59/100 across eight factors for Cardinal Health, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CAH stock overvalued or undervalued?
MELANY's valuation factor currently reads 64/100 for Cardinal Health, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CAH's read.
What price should I buy CAH at?
MELANY is not flagging a fresh entry for CAH at its current Hold rating, so there is no entry zone to publish right now. Watchlisting CAH in the free app gets you alerted the moment that changes.
What are the risks of buying CAH stock?
The top risks MELANY currently flags for Cardinal Health, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Cardinal Health, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 8/100 for Cardinal Health, Inc., and earnings track record, at 98/100. The 59/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CAH stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 65/100 for CAH right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CAH rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CAH continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
CAH's live rating and alerts are free either way. The app is our flagship.